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ABSTRACT
Methicillin-resistant Staphylococcus aureus (MRSA) strains are important nosocomial pathogens world-
wide and now are also of growing importance in community-acquired infection. Their resistance
depends upon a supplementary peptidoglycan transpeptidase, PBP2¢ (PBP-2a), which continues to
function when normal PBPs have been inactivated by b-lactams. PBP2¢ is encoded by the mecA gene,
which is carried by the staphylococcal cassette chromosome, a large and somewhat variable DNA insert
of uncertain origin. PBP2¢ does not wholly lack affinity for b-lactams, but its affinity for available
analogues is very weak. In principle, it should be possible to re-engineer b-lactams to bind PBP2¢
strongly, and the desirability of this approach is self-evident: no other antibiotic class has a record equal
to the b-lactams for safety and efficacy. Moreover, there is consensus that b-lactams are inherently more
efficacious than vancomycin against infections due to susceptible staphylococci. In practice, finding
viable PBP2¢-active b-lactams has proved difficult and the catalogue of near-misses extends back to the
1980s. At last, however, one cephalosporin with high affinity for PBP2¢—ceftobiprole—is entering phase
III trials. Ceftobiprole inhibits MRSA at 1–2 mg ⁄L under standard conditions. Even when mecA ⁄PBP2¢
was induced strongly, ceftobiprole MICs for MRSA only reached 4 mg ⁄L, a clinically attainable
concentration. A phase II trial in skin and skin structure infection recorded cures by ceftobiprole in 4 ⁄ 4
MRSA infections, and results of the phase III trials are awaited with great interest.
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INTRODUCTION
Methicillin-resistant Staphylococcus aureus (MRSA)
strains were first reported in 1961, the year that
methicillin itself reached the market [1]. After
some initial spread during the 1960s, the preval-
ence of MRSA decreased in the late 1970s and
early 1980s, apparently through a combination of
better infection control and increased use of
gentamicin [2].
During the mid-1980s, MRSA strains re-
emerged, although often as colonists rather than
pathogens, with the result that their significance
was debated. In England and Wales, their pre-
valence in severe infections remained low until
the mid-1990s, when the proportion of S. aureus
bacteraemias caused by MRSA rose dramatically,
from 1% to 2% in 1990–1992 to about 40% in 2000
(Fig. 1) [3–5]. This increase coincided with the
emergence of two particular epidemic MRSA
(EMRSA) strains, EMRSA-15 and EMRSA-16,
which began to predominate among MRSA iso-
lates sent to the national reference laboratories for
epidemiological typing (Fig. 2) [3,6,7]. By the late
1990s, these two strains represented over 95% of
all MRSA strains collected from bloodstream
infections in the UK as part of the European
Antimicrobial Resistance Surveillance System [3].
MRSA strains are now widely problematic,
although their prevalence remains low in The
Netherlands and the Scandinavian countries,
owing to exemplary infection control procedures.
The Mediterranean countries and Ireland cur-
rently have MRSA prevalence rates similar to
those in the UK, while rates are steadily rising in
Germany and much of central Europe (Fig. 3)
[8,9]. The MRSA rates in many US and Far Eastern
hospitals are even higher, with proportions as
high as 60% being cited for some centres [10].
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In the UK, at least, the rise in MRSA infections
is in addition to the burden of infections due to
methicillin-susceptible S. aureus (MSSA). This is
illustrated by two similar surveys of clinically
significant isolates from hospital inpatients in the
British Isles carried out a decade apart, in 1991
and 2001 [6,11,12]. These found a steep rise in
MRSA as a proportion of S. aureus isolates, from
0.7% to 14.8%, but also in S. aureus as a propor-
tion of all isolates, from 25.6% to 33.2%.
The rise in MRSA and its impact on hospital
mortality and morbidity is now a frequent topic in
the lay press in the UK, and became a major issue
in the 2005 general election campaign.
MECHANISM OF b -LACTAM
RESISTANCE IN MRSA
The cell wall of Gram-positive bacteria is com-
posed of a single, extensively cross-linked pep-
tidoglycan macromolecule, which confers
strength and rigidity, maintaining the bacterial
shape and protecting against osmotic forces.
Structurally, peptidoglycan is composed of
polysaccharide chains of alternating N-acetylg-
lucosamine and N-acetylmuramic acid sugar res-
idues, which are cross-linked by peptide bridges.
Its synthesis involves three distinct phases. The
first phase, which occurs in the cytoplasm,
involves sequentially adding amino acids (L-alan-
ine, D-glutamine, L-lysine, and a dimer of
D-alanine) to a UDP-linked N-acetylmuramic acid
molecule. In the second phase, this sugar penta-
peptide is transferred from the UDP molecule to a
lipid carrier (bactoprenol), which transports it
across the cytoplasmic membrane, where a fur-
ther N-acetylglucosamine residue is linked to the
N-acetylmuramic acid and, in staphylococci, the
e-amino group of the lysine residue is substituted
by pentaglycine.
During the third phase, which occurs at the
external surface of the cytoplasmic membrane, the
resulting disaccharide-pentapetide is linked onto
an existing polysaccharide chain in a reaction
termed transglycosylation. Cross-linking of the
polysaccharide chains then follows, with attach-
ment via their peptide substituents. This step is
catalysed by multiple D-alanyl-D-alanine trans-
peptidases. They, along with other penicillin-
susceptible (but non-critical) enzymes, are
referred to as penicillin-binding proteins (PBPs)
and are the key targets of b-lactam action.
Fig. 1. Proportion of Staphylococcus aureus bacteraemias
caused by methicillin-resistant S. aureus (MRSA) in Eng-
land and Wales from 1989 to 2004 (open bars) and MRSA
bacteraemias as a proportion of all bacteraemias (solid
bars). Data are based on voluntary reporting to the Health
Protection Agency, now about 70% comprehensive [4,5].
Adapted from Johnson et al. [5] with permission.
Fig. 2. Hospitals in England and Wales referring isolates
of epidemic methicillin-resistant Staphylococcus aureus
(EMRSA) strains 3, 15 and 16 to the then Public Health
Laboratory Service Staphylococcal Reference Unit [6,7].
Reprinted from British Society for Antimicrobial Chemo-
therapy [7] with permission.
Fig. 3. Data from the European Antibiotic Resistance
Surveillance System (EARSS) showing methicillin-resistant
Staphylococcus aureus as a percentage of all S. aureus
bacteraemias in various European countries 1999–2004 [8].
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b-Lactams owe their ability to inhibit these
enzymes to a conformational resemblance to
D-alanyl-D-alanine; in consequence, they irrevers-
ibly inhibit the D-alanyl-D-alanine transpeptidases
by covalent acylation of an active site serine.
S. aureus has three essential PBPs with trans-
peptidase activity, PBP1, PBP2 and PBP3, and all
remain, unaltered, in MRSA. Rather, the resist-
ance of MRSA to b-lactams is mediated by a
supplementary peptidoglycan transpeptidase
PBP, PBP2¢ (also known as PBP2a), which contin-
ues to function when the normal PBPs have been
inactivated by b-lactams [13]. PBP2¢ does bind
some available b-lactams, but only with extremely
weak affinity. It is encoded by an acquired gene,
mecA, which is invariably located on a poorly
mobile genetic element termed the staphylococcal
cassette chromosome mec (SCCmec), and which is
inserted into the S. aureus chromosome at a
specific, consistent position [14]. There are at least
five major staphylococcal cassette chromosome
variants, differing in size and regulatory genes
[15]. Their restriction to a relatively few clonal
complexes of MRSA strains may be because these
are the only lineages that are permissive of mecA
and its product [16], or may simply reflect the
rarity of transfer. Nevertheless, some horizontal
transfer does occur, as evidenced by the facts that
the same SCCmec variants occur in different
clonal complexes, and that some MRSA and
MSSA strains are clonally identical. Moreover,
the same SCCmec variants occur in both MRSA
and coagulase-negative staphylococci [17,18].
TREATMENT OPTIONS AND NEW
DIRECTIONS
The standard treatment options for serious MRSA
infections are the glycopeptides, vancomycin and
teicoplanin, often given together with rifampicin.
According to the susceptibility of the particular
strain, combinations of two or more of fusidic
acid, rifampicin, trimethoprim and minocycline
may also be used in less severe infections or as
oral follow-on treatment to an intravenous glyco-
peptide. In addition, there is a growing list of
recently developed agents for treatment of severe
MRSA infection, with quinupristin–dalfopristin,
daptomycin, linezolid and tigecycline already
licensed in some parts of the world, and dalba-
vancin and telavancin anticipated in the next few
years [19,20]. A major coming challenge will be to
determine to what extent these agents offer
absolute and cost–benefit advantages over vanco-
mycin and to define their relative merits. At the
time of writing, there is limited evidence, based
on subset analysis, to suggest that linezolid is
superior to vancomycin in treating nosocomial
pneumonia due to MRSA [21], while a prospect-
ive study has indicated superiority in treating
skin and skin structure infections [22]. The lack of
wider evidence of superiority is perhaps surpri-
sing because vancomycin is not considered to be
an especially potent antibiotic. In a prospective
study, 19% (13 ⁄ 70) of MSSA bacteraemia patients
treated with vancomycin experienced bacterio-
logical failure, with bacteraemia persisting be-
yond 7 days or with relapse, compared with none
of 18 treated with nafcillin [23]. Similarly, none of
ten patients treated with cloxacillin for MSSA
pneumonia died, compared with 47% (8 ⁄ 17) of
those treated with vancomycin [24]. More gener-
ally—and although much of the evidence is
anecdotal or retrospective—there is wide consen-
sus that b-lactams are more efficacious than
vancomycin against infections due to susceptible
staphylococci.
In principle, it should be possible to redesign b-
lactams so that they bind to PBP2¢, thereby
gaining activity against MRSA. This task should
be facilitated because the crystal structure of
PBP2¢ is known, permitting molecular modelling
[25]. Moreover, PBP2¢ is exposed on the cell
surface, meaning that the antibiotic need not be
a good permeant of bacterial membranes,
whereas this would be a sine qua non for an anti-
Gram-negative agent. The problem lies in the fact
that the active site of PBP2¢ is located in an
extended, narrow groove. The structure of this
groove is such that the b-lactam is displaced and
misaligned with respect to the active site serine
residue, militating against acylation [25,26].
Many attempts have been made to produce
b-lactams with modified side group structures to
promote association with PBP2¢ and to make
acylation more energetically favourable. Modifi-
cations known to enhance activity involve acyl
substituent groups with greater length and
hydrophobicity, which result in increased inter-
action with the active site groove. Such research
has yielded several compounds with MIC values
of 2–8 mg ⁄L for MRSA [26], but it has proved
difficult to develop these for clinical use. One of
the earliest such analogues, an aminothiazolyl
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penicillin called BRL-44154 (Beecham), was inves-
tigated in the 1980s [27] and had MICs of 4–
8 mg ⁄L for MRSA, compared with 0.5–2 mg ⁄L for
MSSA. It was effective against MRSA infections in
mice but was inactivated by rapid metabolism in
humans. A later carbapenem, L-695 256 (Merck),
was even more active in vitro, with MICs of
2 mg ⁄L for MRSA, and was effective against
MRSA endocarditis in rabbits [28]. However, it
readily formed insoluble crystals, making it
unsuitable for use in humans or for commercial
manufacture [29]. Numerous anti-MRSA cephalo-
sporins (e.g., TOC-50) [30] were presented at one
or more ICAAC meetings during the 1990s before
fading from view, usually without publicly avail-
able explanation. More recent anti-MRSA
cephalosporins include RWJ-54428 (now aban-
doned [31]), CAB-175 [32–34] and PPI-0903 (CX-
0903, T-91825, TAK-599) [32], which is in phase I
development, as is an anti-MRSA carbapenem,
CS-023 (RO4908463) [33].
CEFTOBIPROLE
One further anti-MRSA cephalosporin, ceftobi-
prole (Ro 63-9141, BAL9141), has progressed
much further, and is now entering phase III.
Ceftobiprole has an oxyimino aminothiazolyl
substituent linked to the 7-amino group of the
cephalosporin nucleus, conferring stability to
many b-lactamases, and a vinylpyrrolidinone
moiety at position 3, promoting association with
PBP2¢ and facilitating the subsequent acylation
reaction (Fig. 4) (M. Page, personal communica-
tion). PBP assays, which reflect both the initial
binding and the acylation, indicate that ceftobi-
prole produces a 50% saturation of PBP2¢ at
0.87 lM, compared with 115 lM for ceftriaxone
and > 500 lM for imipenem and methicillin [34].
For improved solubility, ceftobiprole is adminis-
tered in vivo as a water-soluble ester prodrug,
ceftobiprole medocaril, which is rapidly cleaved
in plasma to yield the active compound [34].
In tests against 235 S. aureus isolates (95 MRSA,
140 MSSA) from 25 hospitals across the UK
collected as part of the British Society for Anti-
microbial Chemotherapy Resistance Surveillance
Programme, ceftobiprole inhibited MRSA strains
at 1–2 mg ⁄L, compared with 0.25–1 mg ⁄L for
MSSA [35]. Even under growth conditions
strongly inducing mecA ⁄PBP2¢ (30C on Columbia
agar with 2% sodium chloride), the MICs of
ceftobiprole for MRSA did not exceed 4 mg ⁄L
(Fig. 5) (Reynolds R, Livermore DM. Effect of
Culture Conditions on MICs of BAL9141, Repre-
senting a New Class of Cephalosporins Active
against MRSA. 44th ICAAC 2004, abstact E-2036).
Aside from this anti-staphylococcal behaviour,
ceftobiprole has broad-spectrum activity against
pneumococci, other streptococci and most Entero-
coccus faecalis strains, although not Enterococcus
faecium, which is inherently resistant. Ceftobiprole
is also active against most Enterobacteriaceae
except Proteus vulgaris, but loses activity against
isolates with extended-spectrum b-lactamases.
Fig. 4. Molecular model showing ceftobiprole in the active
site of Staphylococcus aureus PBP2¢ (M. Page, personal
communication).
Fig. 5. Activity of ceftobiprole against Staphylococcus aure-
us isolates from 25 UK hospitals tested on two different
culture media conditions, one (Columbia) more inducing
for expression of methicillin resistance [35]. MRSA, meth-
icillin-resistant S. aureus; MSSA, methicillin-susceptible
S. aureus.
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Ceftobiprole has similar activity to cefepime
against Pseudomonas aeruginosa.
Ceftobiprole shows time-dependent bacteri-
cidal activity in vitro against staphylococci and
other organisms (Fig. 6). This bactericidal activity
contrasts with the behaviour of vancomycin,
which causes a modest and slow reduction in
staphylococcal counts, particularly over the initial
hours of exposure [34]. Ceftobiprole contrasts also
with linezolid and tigecycline, which are essen-
tially bacteriostatic. Two other new agents, dap-
tomycin and telavancin, are even more rapidly
cidal than ceftobiprole and it remains to be seen
how these differences translate into efficacy.
Thus far, data on the efficacy of ceftobiprole are
limited but positive, coming from a phase II trial
involving 40 patients with complicated skin and
skin structure infections (Heep M, Querner S,
Harsch M, O’Riordan W. Ceftobiprloe [BAL5788],
the First of a New Class of Anti-MRSA Cepha-
losporins: Microbiological Results from a Phase II
Study in Complicated Skin and Skin Structure
Infections. 44th ICAAC 2004, abstract L-361).
Clinical success was observed in 12 of 15 MSSA
infections and all four MRSA infections. Among
the 23 microbiologically evaluable patients, there
were two cases of microbiological persist-
ence—one with MRSA and one with MSSA. No
increases in ceftobiprole MIC values were ob-
served during treatment. On the basis of these
promising results, ceftobiprole has progressed to
phase III trials, comparing its efficacy and safety
with those of vancomycin in patients with com-
plicated skin and skin structure infections [35].
CONCLUSIONS
MRSA is a high-profile infectious disease prob-
lem, with increasing nosocomial prevalence in
many countries. New MRSA strains are evolving
and are important as community pathogens in the
USA and, less so, Europe [36]. Many of the
community strains aggressively produce Panton–
Valentine leukocidin, and cause rapidly destruc-
tive skin infections.
Although much may be achieved through
better infection control within hospitals, MRSA
seems likely to remain a major problem for years
to come, and many MRSA infections inevitably
will require antimicrobial treatment. Before
MRSA became prevalent, b-lactams were the
preferred anti-staphylococcal agents and it was
only the spread of MRSA that forced the use of
glycopeptides, which most workers consider to be
inferior agents. The route to restoring the activity
of b-lactams lies in designing analogues capable
of binding to PBP2¢, but this has proved a difficult
target, with many disappointments. New PBP2¢-
binding analogues do, however, show encour-
aging activity, and ceftobiprole, the most
advanced of these, is entering phase III develop-
ment. The results of these trials will be watched
with great interest.
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